Physician profile
Michael J Causey
NPI 1033103999
$1,626.10
in general payments reported to CMS, 2019-2025
17 companies · $580 in 2025
The $580 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.70 · 2023: $336 · 2024: $660 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,575.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $319.86 | 2024-2025 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $257.39 | 2023-2025 | Eylea Hd, Eylea |
| Tarsus Pharmaceuticals, INC. | $235.15 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $140.89 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $120.67 | 2022-2025 | Eysuvis, Rocklatan, Clareon |
| Sun Pharmaceutical Industries INC. | $105.64 | 2023-2025 | Cequa |
| Abbvie INC. | $78.26 | 2023-2024 | Ozurdex |
| Genentech USA, INC. | $66.54 | 2024-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $52.62 | 2022-2023 | |
| Harrow Eye, LLC | $42.61 | 2025 | Vevye |
| Thea Pharma INC. | $42.02 | 2022-2023 | Iyuzeh |
| Oyster Point Pharma, INC. | $37.30 | 2023-2024 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $30.31 | 2025 | Oxervate |
| Astellas Pharma US INC | $27.79 | 2025 | Izervay |
| Johnson & Johnson Surgical Vision, INC. | $25.66 | 2024 | Catalys System |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $23.89 | 2023 | Acthar |
| Horizon Therapeutics Plc | $19.50 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Causey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.